Loss of expression of the IGFBPs, IGFBP3 and IGFBP4, has previously been linked with resistance to gefitinib in other cancer types [37] and IGFBP-3 is frequently concomitantly overexpressed with EGFR in ESCC [38]. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.